Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 45th San Antonio Breast Cancer Symposium will host 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
VJOncology will be in attendance to help disseminate the latest learnings from the meeting.
π₯@BenWestphalen of @LMU_Muenchen highlights the transformative impact of KRAS inhibitors, like sotorasib and panitumumab, across oncology, with significant advancements discussed at #ESMO23:
The 45th San Antonio Breast Cancer Symposium will host 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
VJOncology will be in attendance to help disseminate the latest learnings from the meeting.
π₯@BenWestphalen of @LMU_Muenchen highlights the transformative impact of KRAS inhibitors, like sotorasib and panitumumab, across oncology, with significant advancements discussed at #ESMO23:
Watch our latest Breast Cancer VJSession where leading breast cancer experts Sara Tolaney, Sarah Sammons, and Paolo Tarantino review the latest updates in breast cancer from SABCS 2022!
Topics cover updates in capivasertib, latest SERD data including elacestrant and camizestrant and other novel ER degraders, strategies post CDK4/6 inhibition, biomarkers for response to antibody-drug conjugates such as HER2-low and TROP-2, as well as updated PFS from DESTINY-Breast03.
SABCS 2022 featured an array of conversations on the field of HER2-low breast cancer, including updates from the results of DESTINY-Breast02, as well as debates as to whether it should be considered a separate entity.